Obeldesivir for the Treatment of COVID-19 in People With Risk Factors for Progression to Severe Disease: The BIRCH Study

Conference Reports for NATAP

ID Week 2024
October 16-19
Los Angeles, California


Obeldesivir for the Treatment of COVID-19 in People With Risk Factors for Progression to Severe Disease: The BIRCH Study

	IDWeek 2024 Oct 16-19 LA, CA